The specific neutralizing antibody has both preventive and therapeutic effects, and is known as the biological missile aiming at the new coronavirus. As early as the outbreak of Xinguan, the Institute of Microbiology of the Chinese Academy of Sciences started to develop monoclonal antibodies. Using the single B-cell antibody screening platform, multiple antibodies were isolated and screened from patients in convalescent period. They cooperated with the R & D and industrialization teams of enterprises to rapidly carry out multi-channel parallel development and large-scale production of candidate antibodies.
The novel coronavirus pneumonia product JS016, novel coronavirus pneumonia, developed by the Institute of Microbiology in June this year, was approved to become the worlds first clinical trial for new crown pneumonia therapeutic antibody in healthy population. The clinical trial was launched in China and the United States, and all participants in the I phase trial were completed in early July.
According to the Institute of Microbiology of the Chinese Academy of Sciences, the clinical trials of js016 antibody products in the United States are advancing at full speed, and are now in phase II, which is expected to make an important contribution to the epidemic prevention and control in China and the world. (end)